id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id FDA-2026-P-10693-0016,FDA,FDA-2026-P-10693,Exhibit 03 - FDA - Approval Letter for VEMLIDY,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:18Z,,0,0,09000064b951d4ff FDA-2026-P-10693-0018,FDA,FDA-2026-P-10693,Exhibit 05 - Exclusivity Summary for VEMLIDY - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:26Z,,0,0,09000064b9522501 FDA-2026-P-10693-0019,FDA,FDA-2026-P-10693,Exhibit 06 - Wang - On the Single-Crystal Structure of Tenofovir Alafenamide Mono-Fumarate,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:31Z,,0,0,09000064b9522502 FDA-2026-P-10693-0039,FDA,FDA-2026-P-10693,Exhibit 26 - Drugs at FDA - DESCOVY and VEMLIDY,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:01Z,,0,0,09000064b9524324 FDA-2026-P-10693-0058,FDA,FDA-2026-P-10693,Exhibit 45 - Zumdahl - Chemistry,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:35Z,,0,0,09000064b95243b9 FDA-2026-P-10693-0064,FDA,FDA-2026-P-10693,Exhibit 51 - Product Monograph for VEMLIDY,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:12Z,,0,0,09000064b95243f1 FDA-2026-P-10693-0067,FDA,FDA-2026-P-10693,Exhibit 54 - Jones - The CryoEM Method MicroED as a Powerful Tool for Small Molecule Structure Determination,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:23Z,,0,0,09000064b95243f4 FDA-2026-P-10693-0079,FDA,FDA-2026-P-10693,Exhibit 66 - FDA Petition Response to Katherine M Sanzo Lawrence S Ganslaw - Morgan Lewis Bockius et al,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:13Z,,0,0,09000064b9524432 FDA-2026-P-10693-0084,FDA,FDA-2026-P-10693,Exhibit 71 - Orange Book Product Details for NDA 018877,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:37Z,,0,0,09000064b9524487 FDA-2026-P-10693-0090,FDA,FDA-2026-P-10693,Exhibit 77 - LEVOXYL Prescribing Information,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:59Z,,0,0,09000064b952448d FDA-2026-P-10693-0008,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 4 - Lengauer 2020,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:33Z,,0,0,09000064b95244bc FDA-2026-P-10693-0072,FDA,FDA-2026-P-10693,Exhibit 59 - Meet Yale Maestro of MicroED,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:47Z,,0,0,09000064b952442b FDA-2026-P-10693-0075,FDA,FDA-2026-P-10693,Exhibit 62 - Final Brief for Federal Defendants-Appellees,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:59Z,,0,0,09000064b952442e FDA-2026-P-10693-0082,FDA,FDA-2026-P-10693,Exhibit 69 - Amarin Pharma Inc v Apotex Inc,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:24Z,,0,0,09000064b9524485 FDA-2026-P-10693-0083,FDA,FDA-2026-P-10693,Exhibit 70 - Orange Book Product Details for NDA 018832,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:28Z,,0,0,09000064b9524486 FDA-2026-P-10693-0005,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 2 part 1- XtalPi Report,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:21Z,,0,0,09000064b95244b9 FDA-2026-P-10693-0002,FDA,FDA-2026-P-10693,"Acknowledgement Letter from FDA DMB to Gilead Sciences, Inc.",Other,Acknowledgement Letter/Receipt,2026-09-15T04:00:00Z,2026,9,2026-09-15T04:00:00Z,,2026-09-15T17:44:45Z,,0,0,09000064b9523abe FDA-2026-P-10693-0023,FDA,FDA-2026-P-10693,Exhibit 10 - July 29 Notice,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:47Z,,0,0,09000064b95242d8 FDA-2026-P-10693-0031,FDA,FDA-2026-P-10693,Exhibit 18 - FDA - Petition Response to Gary Veron on Behalf of Mutual Pharm Co Inc,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:29Z,,0,0,09000064b952431c FDA-2026-P-10693-0032,FDA,FDA-2026-P-10693,Exhibit 19 - 67 Fed Reg 66593,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:33Z,,0,0,09000064b952431d FDA-2026-P-10693-0033,FDA,FDA-2026-P-10693,Exhibit 20 - DESCOVY Container Label,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:37Z,,0,0,09000064b952431e FDA-2026-P-10693-0036,FDA,FDA-2026-P-10693,Exhibit 23 - TEKTURNA Prescribing Information,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:49Z,,0,0,09000064b9524321 FDA-2026-P-10693-0038,FDA,FDA-2026-P-10693,Exhibit 25 - Orange Book 46th ed - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:58Z,,0,0,09000064b9524323 FDA-2026-P-10693-0042,FDA,FDA-2026-P-10693,Exhibit 29 - Draft Guidance - Ematricitabine TAF,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:15Z,,0,0,09000064b9524377 FDA-2026-P-10693-0056,FDA,FDA-2026-P-10693,Exhibit 43 - USAN Council - Statement on Aliskiren Fumarate,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:27Z,,0,0,09000064b95243b7 FDA-2026-P-10693-0001,FDA,FDA-2026-P-10693,"Citizen Petition from Gilead Sciences, Inc.",Other,Citizen Petition,2026-09-15T04:00:00Z,2026,9,2026-09-15T04:00:00Z,,2026-09-15T17:44:40Z,,1,0,09000064b9523a58 FDA-2026-P-10693-0015,FDA,FDA-2026-P-10693,Exhibit 02 - DESCOVY Prescribing Information,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:13Z,,0,0,09000064b951d4fe FDA-2026-P-10693-0017,FDA,FDA-2026-P-10693,Exhibit 04 - VEMLIDY Prescribing Information,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:22Z,,0,0,09000064b9522500 FDA-2026-P-10693-0020,FDA,FDA-2026-P-10693,Exhibit 07 - Lengauer - Co-crystals Salts or Mixtures of Both,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:35Z,,0,0,09000064b9522503 FDA-2026-P-10693-0022,FDA,FDA-2026-P-10693,Exhibit 09 - July 16 Notice,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:43Z,,0,0,09000064b95242d7 FDA-2026-P-10693-0028,FDA,FDA-2026-P-10693,Exhibit 15 - FDA Petition Response to David Platt MD - Novartis Pharmaceuticals Corp,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:07Z,,0,0,09000064b95242dd FDA-2026-P-10693-0043,FDA,FDA-2026-P-10693,Exhibit 30 - Draft Guidance - Tenofovir Alafenamide Fumarate,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:19Z,,0,0,09000064b9524378 FDA-2026-P-10693-0046,FDA,FDA-2026-P-10693,Exhibit 33 - CDER Product Quality Review Quality Assessment for NDA 209299 TAVALISSE - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:31Z,,0,0,09000064b952437b FDA-2026-P-10693-0047,FDA,FDA-2026-P-10693,Exhibit 34 - CDER Pharmacology Review for NDA 207561 GENVOYA - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:35Z,,0,0,09000064b952437c FDA-2026-P-10693-0052,FDA,FDA-2026-P-10693,Exhibit 39 - USAN Council - Statement of a Nonproprietary Name Adopted - TAM,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:11Z,,0,0,09000064b95243b3 FDA-2026-P-10693-0062,FDA,FDA-2026-P-10693,Exhibit 49 - CONFIDENTIAL DESCOVY NDA - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:55Z,,0,0,09000064b95243ef FDA-2026-P-10693-0069,FDA,FDA-2026-P-10693,Exhibit 56 - Kuballa Liquid Nuclear Magnetic Resonance,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:33Z,,0,0,09000064b95243f6 FDA-2026-P-10693-0070,FDA,FDA-2026-P-10693,Exhibit 57 - Guidance - ANDAs Pharmaceutical Solid Polymorphism,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:38Z,,0,0,09000064b95243f7 FDA-2026-P-10693-0074,FDA,FDA-2026-P-10693,Exhibit 61 - Mooney - Nitrogen Magnetic Resonance Spectroscopy,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:55Z,,0,0,09000064b952442d FDA-2026-P-10693-0089,FDA,FDA-2026-P-10693,Exhibit 76 - NOVOTHYROX Prescribing Information,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:55Z,,0,0,09000064b952448c FDA-2026-P-10693-0004,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 1 - Mercado CV,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:15Z,,0,0,09000064b95244b8 FDA-2026-P-10693-0013,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 9 - Wang 2020,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:53Z,,0,0,09000064b9525939 FDA-2026-P-10693-0025,FDA,FDA-2026-P-10693,Exhibit 12 - Draft Guidance - Determining Whether to Submit an ANDA,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:55Z,,0,0,09000064b95242da FDA-2026-P-10693-0026,FDA,FDA-2026-P-10693,Exhibit 13 - Draft Guidance - Applications Covered by Section 505,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:59Z,,0,0,09000064b95242db FDA-2026-P-10693-0029,FDA,FDA-2026-P-10693,Exhibit 16 - Guidance - Regulatory Classification of Pharmaceutical Co-Crystals,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:20Z,,0,0,09000064b95242de FDA-2026-P-10693-0037,FDA,FDA-2026-P-10693,Exhibit 24 - TEKTURNA Prescribing Information,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:53Z,,0,0,09000064b9524322 FDA-2026-P-10693-0045,FDA,FDA-2026-P-10693,Exhibit 32 - CDER Chemistry Review for NDA 208215 DESCOVY - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:27Z,,0,0,09000064b952437a FDA-2026-P-10693-0054,FDA,FDA-2026-P-10693,Exhibit 41 - WHO Guidance - Use of INNs,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:19Z,,0,0,09000064b95243b5 FDA-2026-P-10693-0057,FDA,FDA-2026-P-10693,Exhibit 44 - Novartis Pharmaceuticals Corporation v Becerra,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:31Z,,0,0,09000064b95243b8 FDA-2026-P-10693-0059,FDA,FDA-2026-P-10693,Exhibit 46 - Cruz-Cabeza - The Role of Solvation in Proton Transfer Reactions,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:39Z,,0,0,09000064b95243ba FDA-2026-P-10693-0066,FDA,FDA-2026-P-10693,Exhibit 53 - Newman From Powders to Single Crystals,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:19Z,,0,0,09000064b95243f3 FDA-2026-P-10693-0078,FDA,FDA-2026-P-10693,Exhibit 65 - FDA Petition Response to Scott H Korn MD FACP - Merck Sharpe Dohme Corp,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:09Z,,0,0,09000064b9524431 FDA-2026-P-10693-0081,FDA,FDA-2026-P-10693,Exhibit 68 - Draft Guidance - Safety Labeling Changes,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:20Z,,0,0,09000064b9524484 FDA-2026-P-10693-0091,FDA,FDA-2026-P-10693,Exhibit 78 - Guidance - Evaluation of Therapeutic Equivalence,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:52:03Z,,0,0,09000064b95244b6 FDA-2026-P-10693-0012,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 8 - Clabbers 2022,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:49Z,,0,0,09000064b9525938 FDA-2026-P-10693-0014,FDA,FDA-2026-P-10693,Exhibit 01 - FDA - Approval Letter for DESCOVY,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:10Z,,0,0,09000064b951d4fd FDA-2026-P-10693-0024,FDA,FDA-2026-P-10693,Exhibit 11 - Guidance - Determining Whether to Submit an ANDA,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:51Z,,0,0,09000064b95242d9 FDA-2026-P-10693-0030,FDA,FDA-2026-P-10693,Exhibit 17 - 54 Fed Reg 28872,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:25Z,,0,0,09000064b95242df FDA-2026-P-10693-0034,FDA,FDA-2026-P-10693,Exhibit 21 - VEMLIDY Container Label,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:41Z,,0,0,09000064b952431f FDA-2026-P-10693-0044,FDA,FDA-2026-P-10693,Exhibit 31 - Draft Guidance - Daclatasvir Dihydrochloride,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:24Z,,0,0,09000064b9524379 FDA-2026-P-10693-0048,FDA,FDA-2026-P-10693,Exhibit 35 - CONFIDENTIAL Letter from FDA to Gilead,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:42Z,,0,0,09000064b952437d FDA-2026-P-10693-0051,FDA,FDA-2026-P-10693,Exhibit 38 - Draft Guidance - Sameness Evaluation in ANDA,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:06Z,,0,0,09000064b95243b2 FDA-2026-P-10693-0053,FDA,FDA-2026-P-10693,Exhibit 40 - AMA US Adopted Names Naming Guidelines,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:15Z,,0,0,09000064b95243b4 FDA-2026-P-10693-0055,FDA,FDA-2026-P-10693,Exhibit 42 - Orange Book 28th Ed - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:23Z,,0,0,09000064b95243b6 FDA-2026-P-10693-0061,FDA,FDA-2026-P-10693,Exhibit 48 - CONFIDENTIAL GENVOYA NDA - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:51Z,,0,0,09000064b95243ee FDA-2026-P-10693-0068,FDA,FDA-2026-P-10693,Exhibit 55 - Reif Solid-state NMR spectroscopy,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:27Z,,0,0,09000064b95243f5 FDA-2026-P-10693-0076,FDA,FDA-2026-P-10693,Exhibit 63 - FDA Petition Response to Thomas A Hayes MD - Bristol-Myers Squibb Co,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:03Z,,0,0,09000064b952442f FDA-2026-P-10693-0077,FDA,FDA-2026-P-10693,Exhibit 64 - 41 Fed Reg 51085,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:06Z,,0,0,09000064b9524430 FDA-2026-P-10693-0085,FDA,FDA-2026-P-10693,Exhibit 72 - Supplement Approval Letter for NDA 018832,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:41Z,,0,0,09000064b9524488 FDA-2026-P-10693-0088,FDA,FDA-2026-P-10693,Exhibit 75 - LEVO-T Prescribing Information,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:51Z,,0,0,09000064b952448b FDA-2026-P-10693-0007,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 3 - Bruhn 2021,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:29Z,,0,0,09000064b95244bb FDA-2026-P-10693-0009,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 5 - Nakai 2025,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:37Z,,0,0,09000064b95244bd FDA-2026-P-10693-0021,FDA,FDA-2026-P-10693,Exhibit 08 - Cheng - Tenofovir Alafenamide Fumarate,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:46:39Z,,0,0,09000064b95242d6 FDA-2026-P-10693-0027,FDA,FDA-2026-P-10693,Exhibit 14 - 68 Fed Reg 36676,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:03Z,,0,0,09000064b95242dc FDA-2026-P-10693-0035,FDA,FDA-2026-P-10693,Exhibit 22 - Guidance - Naming of Drug Products Containing Salt Drug Substances,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:47:45Z,,0,0,09000064b9524320 FDA-2026-P-10693-0040,FDA,FDA-2026-P-10693,Exhibit 27 - Drugs at FDA - FAQs,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:06Z,,0,0,09000064b9524325 FDA-2026-P-10693-0041,FDA,FDA-2026-P-10693,Exhibit 28 - Drugs at FDA - TEKTURNA,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:11Z,,0,0,09000064b9524376 FDA-2026-P-10693-0049,FDA,FDA-2026-P-10693,Exhibit 36 - ODOMZO Prescribing Label,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:48:58Z,,0,0,09000064b952437e FDA-2026-P-10693-0050,FDA,FDA-2026-P-10693,Exhibit 37 - European Medicines Agency Assessment Report,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:02Z,,0,0,09000064b952437f FDA-2026-P-10693-0060,FDA,FDA-2026-P-10693,Exhibit 47 - Klein - Organic Chemistry - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:45Z,,0,0,09000064b95243bb FDA-2026-P-10693-0063,FDA,FDA-2026-P-10693,Exhibit 50 - CONFIDENTIAL CMC Amendment,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:49:59Z,,0,0,09000064b95243f0 FDA-2026-P-10693-0065,FDA,FDA-2026-P-10693,Exhibit 52 - European Medicines Agency - Assessment Report for VEMLIDY - Excerpt,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:15Z,,0,0,09000064b95243f2 FDA-2026-P-10693-0071,FDA,FDA-2026-P-10693,Exhibit 58 - Nakai - Detection of Hydrogen Atoms Using Only 3D ED MicroED,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:42Z,,0,0,09000064b952442a FDA-2026-P-10693-0073,FDA,FDA-2026-P-10693,Exhibit 60 - Cambridge English Dictionary - SUBSTANTIAL,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:50:51Z,,0,0,09000064b952442c FDA-2026-P-10693-0080,FDA,FDA-2026-P-10693,Exhibit 67 - FDA - Paragraph IV Patent Certifications,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:16Z,,0,0,09000064b9524433 FDA-2026-P-10693-0086,FDA,FDA-2026-P-10693,Exhibit 73 - ALLOPURINOL Prescribing Information,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:44Z,,0,0,09000064b9524489 FDA-2026-P-10693-0087,FDA,FDA-2026-P-10693,Exhibit 74 - ZYLOPRIM Approval Package,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:51:48Z,,0,0,09000064b952448a FDA-2026-P-10693-0003,FDA,FDA-2026-P-10693,Appendix 1 - Mercado Declaration,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:08Z,,0,0,09000064b95244b7 FDA-2026-P-10693-0006,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 2 part 2 - XtalPi Report References,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:25Z,,0,0,09000064b95244ba FDA-2026-P-10693-0010,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 6 - Ge 2024,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:41Z,,0,0,09000064b95244be FDA-2026-P-10693-0011,FDA,FDA-2026-P-10693,Appendix 1 Exhibit 7 - Hoser 2025,Supporting & Related Material,Background Material,2026-09-15T04:00:00Z,2026,9,,,2026-09-15T17:45:45Z,,0,0,09000064b95244bf